Table 2 A brief overview of research work done on nanofibers for transdermal delivery of anti-inflammatory drugs
S. No | Drug | Polymer | Drug loading (%)/diameter (nm) | Sophisticated techniques used for characterization/animal model used | Key findings | Ref |
|---|---|---|---|---|---|---|
1 | Naproxen | Thermo plastic polyurethane | Not given/523.66–723.50 | SEM, FT-IR, TGA/not given | Nanofibers composed of 10% (w/w) solution of thermoplastic polyurethane showed smooth texture and release of naproxen from nanofibrous mat was greatly affected by its thickness | [69] |
2 | Plai oil | Poly (lactic) acid | 29.95 ± 1.25/0.38 µm | SEM, FT-IR, TGA, DSC, XRD/not given | Nanofibers containing 30% weight plai oil showed the highest in-vitro skin permeation in the reconstructed human epidermis (EpiSkin™) followed by minimum skin irritation indicating their suitability for transdermal delivery | [70] |
3 | Diclofenac sodium | Cellulose acetate | Not given/0.5 µm | Not given/not given | Cellulose acetate based nanofibers showed uniform distribution of diclofenac sodium and high wettability followed by the release of only 30% diclofenac sodium during the first three hours of the release study | [71] |
4 | Sulindac | Polyvinyl alcohol-co-polyethylene | 92/461 | SEM, FT-IR, TGA, DSC/not given | Sulindac loaded nanofibers showed high drug loading, in-vitro stability followed by high in-vitro skin permeation of sulindac compared to patch available in the market | [72] |
5 | Tetrahydro curcumin | Poly caprolactone, polyethylene glycol | 95/400 ± 20 | SEM, FT-IR, TGA, DSC, XRD/not given | Nanofibers composed of polycaprolactone (10% w/v) and polyethylene glycol (5% w/v) in a 2:1 ratio showed excellent morphology and high in-vitro shear adhesion followed by the extended in-vitro release of tetrahydro curcumin for 24 h | [73] |